IMPROVEMENT AND CHALLENGES IN UNDERSTANDING EPILEPSY: A COMPREHENSIVE REVIEW

Chander Hans[1,] Ram Babu Sharma[2], Swati Kaushal[3]*
1 student B Pharm 4th year
2 Prof and Principal
3 Assistant Professor Pharmacology
Himalayan Institute of Pharmacy, Kala amb, Himachal Pradesh

Abstract:

Epilepsy is a serious neurological illness affecting around 50 million individuals globally. Almost 30% of epileptic patients have pharmacoresistance, which is linked to social isolation, dependent behaviour, poor marriage rates, unemployment, psychiatric problems, and a lower quality of life. The efficacy of currently available antiepileptic medicines is limited, and their unfavourable qualities limit their usage and create issues in patient care. Antiepileptic medicines can only provide symptomatic relief because they reduce seizures but cannot cure epileptogenesis. The long-term use of antiepileptic medications is limited due to their side effects, withdrawal symptoms, negative interactions with other drugs, and economic load, particularly in developing nations. Furthermore, several existing antiepileptic medicines may exacerbate some types of seizures. Several in vivo and in vitro animal models have been presented, and numerous novel antiepileptic medications have lately been approved, however a considerable percentage of patients remain pharmacoresistant. This study will focus on the challenges associated with epilepsy therapy and management, as well as the limits of existing antiepileptic medicines and animal seizure models.

Keywords: antiepileptic, anticonvulsant, seizure, pharmaco-resistance, refractory seizures

---

Introduction:

Epilepsy, a chronic neurological condition marked by recurring seizures, affects millions of individuals worldwide. Seizures are caused by aberrant electrical activity in the brain, which can show as a variety of physical and cognitive symptoms. While standard antiseizure drugs (ASMs) have been the foundation of epilepsy management for decades, a sizable minority of patients continue to have seizures after treatment. This has prompted the investigation of novel therapeutics and developing trends in epilepsy management in order to meet the unmet medical needs of people living with drug-resistant epilepsy. Epilepsy management has progressed significantly from its earliest accounts in ancient sources, but problems remain. [1,17]

Traditional ASMs have been linked to deleterious consequences such as cognitive impairment, mood problems, and systemic toxicity. Furthermore, certain epilepsy disorders may be highly resistant to traditional therapies, necessitating novel ways to get better results. [1]

This study will look at the most recent advances in epilepsy care, with an emphasis on developing trends and breakthrough therapies that provide new hope to those with drug-resistant epilepsy. By spotlighting these ground-breaking approaches, we hope to shed light on potentially transformative changes in the sector and their consequences for patient care. In the following sections, we will look at various cutting-edge therapies and research areas that have showed promise in recent years. These include responsive neurostimulation (RNS), vagus nerve stimulation (VNS), deep brain stimulation (DBS), closed-loop stimulation, cannabidiol (CBD) as a novel adjunct therapy, the ketogenic diet, gene therapies, and the fascinating potential of optogenetics. [1,29]

Our key goals for this review are to present a complete summary of the current state of epilepsy care, emphasising the limitations of traditional ASMs and the necessity for alternative therapeutic methods. We sought to give the most recent results and clinical evidence on developing therapies such as RNS, VNS, DBS, closed-loop stimulation, CBD, the ketogenic diet, gene therapies, and optogenetics. The efficacy, safety, and tolerability of these new medicines in reducing seizure frequency and enhancing overall quality of life for epilepsy patients are also discussed. In addition, we explore the putative mechanisms of action underpinning these medications, as well as the consequences for epilepsy pathogenesis.[1,11]

Traditional Approaches to Epilepsy Management

For decades, conventional ASMs have formed the foundation of epilepsy treatment, delivering significant relief to a large number of patients. ASMs work by modulating neuron excitability, which inhibits the aberrant electrical activity that causes seizures. The introduction of these drugs has transformed epilepsy treatment, aiding in seizure control and increasing the quality of life for many people with epilepsy. There are several types of ASMs available, each focusing on unique systems involved in seizure production and propagation. Common ASMs include phenytoin, carbamazepine, valproate, lamotrigine,

and levetiracetam. These medications are usually administered based on the patient's seizure type, epilepsy syndrome, age, and general health. [2]

Despite their widespread usage and effectiveness in a large proportion of patients, ASMs have limitations that can impede successful epilepsy therapy. First, not all patients respond well to standard ASMs, resulting in drug-resistant epilepsy. According to estimates, around one-third of persons with epilepsy continue to have seizures despite receiving appropriate treatment with two or more ASMs. This occurrence presents a substantial clinical problem, emphasising the need for alternate therapeutic approaches to drug-resistant epilepsy. [2,9]

Difficulties in Managing Seizures with Traditional Therapies

Drug-resistant epilepsy is a significant clinical challenge in epilepsy therapy. Patients who are resistant to standard ASMs experience repeated seizures, which can have a significant impact on their everyday lives, disrupt social relationships, and limit educational and employment chances. The unexpected nature of seizures can cause worry, despair, and a lower overall quality of life. The causes of treatment resistance in epilepsy are complicated and multifaceted. Epilepsy's inherent variability is a substantial problem. The illness is diverse, with underlying causes and mechanisms that vary widely from patient to patient. As a result, ASMs that work well for one person may not work as well for another because to variances in brain anatomy and function. [3]

Traditional therapies struggle to produce consistent seizure control due to the wide range of epilepsy subtypes, seizure patterns, and treatment responses. Pharmacokinetic variability is another element that contributes to treatment resistance. The way ASMs are metabolised and transported in the body varies between individuals, influencing medication levels and therapeutic efficacy. medication interactions and genetic variables can potentially have an impact on AED metabolism, resulting in varying medication responses and treatment results. This variability in medication levels can lead to inadequate seizure control and contribute to treatment resistance. Furthermore, ASMs' modes of action may not cover all elements of seizure development and transmission. [4]

This variability in medication levels can lead to inadequate seizure control and contribute to treatment resistance. Furthermore, ASMs' modes of action may not cover all elements of seizure development and transmission. While these drugs generally target ion channels and neurotransmitter receptors, certain epilepsy syndromes may include complex neuronal networks that are less susceptible to standard ASMs. As a result, ASM therapy alone may not be sufficient to provide complete seizure control in some individuals. Compliance difficulties play an important role in treatment resistance. Adherence to recommended AED regimens is critical for effective seizure treatment.[5]

However, poor medication adherence might diminish therapeutic effectiveness and contribute to resistance. Forgetfulness, pharmaceutical side effects, and the difficulty of several daily dosages can all make it difficult for patients to stick to their treatment plans consistently.

Tolerance and adaptation pose additional obstacles in epilepsy management. Some people may build a tolerance to the effects of ASMs over time, resulting in less seizure control. The brain's adaptability and compensating mechanisms may diminish the long-term efficacy of some drugs, necessitating the use of alternative therapeutic techniques. Furthermore, ASMs may cause side effects that affect therapy adherence and tolerance. Some patients may develop severe side effects, including dizziness, sleepiness, cognitive impairment, and mood swings. [5]

Addressing the difficulties of drug-resistant epilepsy necessitates a multifaceted and tailored strategy. As we explore the world of new medicines, it is critical to remember that classic ASMs continue to play a crucial role in the treatment of epilepsy for many patients. However, the limits of existing therapies highlight the need for novel and tailored treatments. Understanding the complexity of treatment resistance and identifying novel targets, such as specific genes or neuronal circuits, could allow researchers to design more effective medicines to improve seizure control and the quality of life for epileptic patients.

As we move forward, collaboration among researchers, physicians, and patients will be critical in advancing the science of epilepsy management, bringing us closer to the day when drug-resistant epilepsy is a thing of the past. The pursuit of emerging trends and creative therapeutics, as well as a better knowledge of the underlying mechanisms of epilepsy, provides hope for greater therapeutic alternatives and a brighter future for those living with the condition. Through ongoing study, dedication, and unwavering devotion, we can improve the lives of those suffering from epilepsy and pave the way for more effective and personalised treatments. [6]

The Need for Novel Treatment Approaches for Drug-Resistant Epilepsy

The persistence of drug-resistant epilepsy emphasises the crucial need for new and innovative treatment options. In recent years, research and clinical efforts have increased to create medicines for specific epilepsy subtypes, uncover novel drug targets, and investigate non-pharmacological therapy. The development of new technology and a better knowledge of the underlying mechanisms of epilepsy have cleared the door for novel therapeutic approaches. Neurostimulation devices, such as RNS, VNS, and DBS, may be viable alternatives for individuals who do not respond to standard ASMs. Furthermore, improvements in precision medicine and personalised techniques provide promise for personalising therapies to particular patients. [7]

Based on their distinct genetic and molecular characteristics. Gene therapies are also being investigated as potential treatments for some genetic epilepsy conditions. [8]



Figure 1. Recent technologies and therapies used in the management of epilepsy. [8]

Non-pharmacological therapies, such as the ketogenic diet and CBD, have gained popularity due to its anticonvulsant qualities, which have demonstrated benefits in lowering seizure frequency in some individuals. The limitations of existing medicines highlight the need to investigate and apply novel treatments to enhance outcomes for people with epilepsy. [8]

Responsive Neurostimulation

Responsive neurostimulation (RNS) is a cutting-edge technique that offers personalised and adaptive treatment for drug-resistant epilepsy. The RNS system comprises of a small neurostimulator device surgically implanted in the skull, as well as one or two intracranial electrodes inserted in or near the epileptogenic brain region responsible for seizure start. The device is based on the core idea of closed-loop neurostimulation, which involves continually monitoring brain activity and delivering electrical stimulation in response to detected aberrant patterns. RNS's mode of action is as follows:

(1) Monitor brain activity: The implanted electrodes continuously record electrical impulses from the brain, identifying small changes that occur before a seizure. Advanced algorithms in the RNS system analyse recorded brain activity in real time.
(2) Detecting seizure onset: RNS the system is set up to recognise certain patterns of electrical activity linked with the onset of a seizure. This personalised detection system is designed for each individual based on their specific seizure characteristics.
(3) Responsive stimulation: When the device identifies a predefined seizure behaviour, it sends short electrical pulses to the epileptic brain region. The stimulation is designed to disrupt the aberrant brain firing patterns and keep the seizure from fully developing.
(4) Adaptation and Learning: The RNS system is intended to adapt and learn over time. Because it continuously analyses brain activity and stimulation effectiveness, it may fine-tune its algorithms to optimise seizure detection and stimulation parameters for each patient, hence improving treatment efficacy. [9]

Clinical trials and real-world evidence confirm RNS's efficacy in reducing seizure frequency and increasing the quality of life for people with drug-resistant epilepsy. In a crucial clinical trial, the RNS system showed considerable advantages to patients with medically resistant focal epilepsy. Participants in the trial had an average of eight or more debilitating partial-onset seizures per month, despite receiving repeated ASM treatments. RNS-treated patients reported a significant reduction in seizure frequency, with a median drop of 44% at one year and 53% at two years following implantation. [9]

Furthermore, long-term follow-up investigations and real-world experiences have confirmed the excellent findings of the initial clinical trial. Real-world evidence has indicated that RNS reduces seizures in a sustained and persistent manner, leading to improved seizure control and quality of life for patients over time. Furthermore, RNS has shown remarkable efficacy in patients with seizures originating from specific brain regions that are not susceptible to resective surgery, giving it a valuable therapy option for people who are not candidates for other surgical procedures. [10]

Potential adverse effects and safety considerations in RNS

As with any medical intervention, RNS has possible side effects and safety concerns. However, it is critical to understand that the risks associated with RNS are often tolerable and frequently surpassed by the benefits of seizure reduction. The surgical hazards involved in implanting the RNS system are typical of those associated with brain surgery, such as infection, haemorrhage, and anesthesia-related problems. However, breakthroughs in neurosurgery have reduced the likelihood of these problems. There may be some stimulation-related adverse effects of RNS. For example, some patients may experience modest side effects from electrical stimulation, such as tingling sensations, muscular spasms, or changes in mood or cognition. [10]

These effects are typically transitory and fade over time as the brain adjusts to the stimulation. Nonetheless, hardware-related difficulties may arise throughout the RNS procedure. The RNS system is a sophisticated medical gadget that requires ongoing monitoring and maintenance. Battery replacements and system changes may be required over time, and patients should continue to receive care from a specialised epilepsy team. [11]

Research suggests that RNS may have cognitive and memory consequences. While RNS is intended to reduce cognitive side effects, some people may have moderate cognitive alterations, especially in the early phases of treatment. These effects are frequently localised to the brain region being stimulated and are typically reversible with stimulation parameter adjustments. [11]

Nonetheless, RNS is a potential and unique treatment option for drug-resistant epilepsy. RNS, which provides adaptive and personalised treatment based on real-time brain activity, has the potential to considerably reduce seizure frequency and enhance quality of life for individuals who have not responded to traditional ASMs. Although there are some potential adverse effects and safety concerns with the treatment, the benefits of increased seizure control and quality of life make RNS an important addition to the arsenal of epilepsy management choices. Nonetheless, it is critical to remember that RNS, along with deep brain and closed-loop stimulation, requires intracranial EEG monitoring. [12]

Surgical device implantation is essentially limited to a small population of patients. This limitation stems from the rigorous assessment and personalised implantation procedures required by the invasive nature of these therapies. While acknowledging this limitation, it is important to note that the potential benefits of RNS, particularly for patients who have exhausted other treatment options, highlight the ongoing need for research and technological advancements to make this approach more accessible and expand its impact in the field of epilepsy management. [12]

Vagus Nerve Stimulation

Vagus nerve stimulation (VNS) is a neuromodulation therapy that includes implanting a device to stimulate the vagus nerve, a main nerve that connects the brainstem to numerous organs in the body, including the heart and digestive system. The VNS system is made up of a tiny generator that is normally implanted beneath the skin in the chest and coupled to a lead wire wrapped around the left vagus nerve in the neck. The specific mechanism by which VNS produces anticonvulsant effects is unknown, however it is thought to entail a number of interrelated mechanisms. [13]

The vagus nerve regulates a variety of physical activities, and activation is hypothesised to influence the balance of neuronal activity in the brain, favouring inhibitory pathways and dampening excessive excitatory activity, which can contribute to seizures. [13]

VNS is intended to give continuous, intermittent electrical stimulation to the vagus nerve within predefined parameters. This stimulation has been demonstrated to lessen the frequency and severity of seizures in patients with drug-resistant epilepsy. VNS works by modifying the activity of brain areas implicated in seizure formation, preventing the propagation of aberrant electrical activity and disrupting the genesis of seizures. [14]

VNS is most commonly utilised as an adjuvant therapy for individuals with partial-onset seizures who have not responded well to standard ASMs. Clinical trials have shown that VNS can significantly reduce seizure frequency, with some patients having a 50% or greater reduction. Furthermore, the benefits of VNS seem to increase with time, with long-term treatment associated with even better seizure control. [15]

Recent Developments in VNS Technology

In recent years, advances in VNS technology have centred on improving treatment efficacy and patient convenience. One significant advancement is the development of closed-loop or on-demand VNS systems, often known as responsive VNS. These devices use real-time EEG monitoring to detect seizure activity and automatically give VNS stimulation when abnormal brain activity is identified. [16]

Furthermore, advances in device design and programming have enabled more personalised and precise stimulation parameters. Clinicians can now adapt VNS settings to specific patients, altering stimulation parameters such pulse width, frequency, and strength to improve treatment response. This customisation allows for a more patient-centered approach, which could lead to better seizure control and tolerability. Furthermore, rechargeable VNS devices are being created, which eliminates the need for frequent battery replacement procedures. These devices can be recharged externally, making treatment more convenient for patients and alleviating the stress of repeated surgical procedures. [16]

Ongoing research and clinical trials on VNS for various epilepsy syndromes

VNS remains an active research topic, with current clinical trials looking into its potential advantages for a variety of epileptic types and patient demographics. Researchers are looking at the safety and efficacy of VNS in children with drug-resistant epilepsy. Early intervention with VNS may be beneficial in reducing cognitive and developmental impairments associated with uncontrolled seizures in paediatric patients. Lennox-Gastaut. [17]

The Lennox-Gastaut syndrome (LGS) is a severe and resistant childhood epilepsy syndrome [87]. Clinical trials are being conducted to determine the effectiveness of VNS in lowering drop attacks and other seizure types associated with LGS. Ongoing research and clinical trials are also looking into the use of VNS in additional epilepsy syndromes, with the goal of expanding the number of patients who can benefit from this revolutionary treatment. [18]

However, drug-resistant focal epilepsy patients may benefit the most from VNS. This includes looking into potential biomarkers and predicting factors for VNS response. Novel VNS techniques, such as non-invasive vagus nerve stimulation, are being investigated for their efficacy as a less invasive alternative to conventional VNS therapy. Some research are looking into the potential synergistic benefits of combining VNS with other neuromodulation techniques or certain ASMs for better seizure management. As VNS research advances, ongoing clinical trials hold the possibility of further understanding VNS's therapeutic potential in diverse epileptic syndromes and fine-tuning patient selection criteria for best

results. As a result, the current consensus is that VNS has emerged as an effective supplementary therapy for drug-resistant epilepsy. [19]

Electrical impulses directed at the vagus nerve's afferent fibres may mistakenly influence respiratory centres in the brainstem, thereby altering breathing patterns during sleep. An increase in the apnea-hypopnea index indicates an increase in sleep apnea events, which are characterised by pauses in breathing or shallow breathing while sleeping. The intricate interplay between brain regulation, vagal stimulation, and respiratory control highlights the importance of careful monitoring and individualised techniques when using VNS as a supplementary therapy for epilepsy. By addressing the extensive network of neuronal interactions and physiological repercussions, we provide physicians, researchers, and individuals considering VNS as part of their therapeutic plan with a more comprehensive perspective. [20]

Deep Brain Stimulation

Deep brain stimulation (DBS) is an advanced neuromodulation technology that has showed promise in the treatment of epilepsy, particularly in people who have drug-resistant episodes. DBS was originally created to treat movement disorders like Parkinson's disease, but it has since evolved into a promising therapeutic option for individuals whose epilepsy remains uncontrolled despite medication and surgical therapies. Unlike typical open-loop neurostimulation, DBS is intended to transmit electrical impulses to specific brain regions in a regulated and targeted manner, with the goal of modulating abnormal neural activity associated with seizure genesis. DBS for epilepsy often targets specific brain areas known to have a role in seizure genesis and propagation. [20]

The reason for targeting the ANT stems from its involvement in the limbic system, which regulates emotions and behaviours, including seizure activity. The goal of applying electrical stimulation to the ANT is to change the network dynamics of the limbic system, successfully decreasing the excessive excitability that might lead to seizure development. DBS prevents the propagation of aberrant electrical activity throughout the brain by altering the synchronisation of neuronal firing patterns, lowering the risk of seizures. Furthermore, several studies have looked at alternative targets, such as the hippocampus and subthalamic nucleus, with promising outcomes in certain patient populations. [21]

Clinical Evidence Illustrating the Efficacy and Safety of DBS

DBS shows potential as a neuromodulation method for the treatment of drug-resistant epilepsy. DBS targets specific brain regions implicated in seizure genesis in order to control neuronal activity and interrupt the transmission of aberrant electrical patterns. Several clinical studies and case reports have demonstrated the efficacy and safety of DBS in lowering seizure frequency and increasing overall seizure control in drug-resistant epilepsy. [22]

These case studies have repeatedly shown that DBS improves seizure control and have provided useful insights into patient selection criteria, appropriate stimulation parameters, and the potential dangers and benefits of the treatments. In terms of safety, DBS has been well tolerated by the vast majority of patients. Adverse effects from stimulation are usually modest and temporary, such as tingling sensations or muscle contractions. Serious problems are uncommon, but can include infection, lead migration, or hardware concerns. Overall, the hazards are associated

The risks associated with DBS must be carefully evaluated against the possible benefits, especially in patients with severe and drug-resistant epilepsy. [23]

Closed-Loop Stimulation

Closed-loop stimulation, also known as on-demand or responsive stimulation, is a novel neurostimulation technique that significantly improves upon classic open-loop neurostimulation. While open-loop neurostimulation entails sending electrical impulses at predetermined intervals or continuous patterns, closed-loop devices alter stimulation dynamically in response to real-time feedback from the patient's brain activity. This real-time feedback is often obtained by continuously monitoring brain signals, such as electroencephalography (EEG) or electrocorticography (ECoG), which provide important information on the brain's electrical activity. [24]

The fundamental benefit of closed-loop stimulation is its capacity to adapt to the patient's physiological state and dynamically intervene at the first signals of abnormal brain activity, such as pre-seizure or prodromal patterns. Closed-loop systems may identify these patterns in real time and administer targeted stimulation precisely when and where it is needed, effectively preventing seizure progression before it occurs. This personalised strategy not only increases neurostimulation efficacy, but also reduces the danger of overstimulation and related negative effects associated with continuous, open-loop stimulation. [25]

Recent Studies and Trials Evaluating Closed-Loop Systems

Recent research and clinical trials on closed-loop devices have yielded promising results in preventing seizures and increasing seizure management in individuals with drug-resistant epilepsy. The NeuroPace RNS System is a remarkable closed-loop stimulation device that has undergone clinical trials. The clinical trial for this approach showed a significant reduction in seizures in patients with medically refractory focal epilepsy. The results showed that patients had a median reduction in seizure frequency of 70% 12-15 months after implantation. Furthermore, a subset of patients experienced a significantly higher reduction in seizures, demonstrating the possibility for substantial seizure control with closed-loop stimulation. [26]

Furthermore, closed-loop devices have been shown to detect and respond to specific brain patterns associated with seizures, allowing for the optimisation of stimulation parameters and personalised treatment. Some investigations have demonstrated that closed-loop stimulation can be adjusted to specific patients, resulting in higher efficacy than traditional open-loop techniques. [27]

Potential for Personalized Closed-Loop Approaches

The possibility for personalised closed-loop techniques in epilepsy therapy is an especially fascinating field of study. Each person's epilepsy is unique, with different seizure kinds, triggers, and brain activity patterns. Closed-loop systems have the intrinsic ability to capture and analyse individual variability, enabling for the formulation of tailored treatment plans. Closed-loop devices can adapt the timing, intensity, and stimulation site to each patient's distinct seizure patterns and needs by using patient-specific data such as EEG or ECoG recordings, genetic profiles, and clinical history. A closed-loop device, for example, can be configured to detect early indicators of seizure activity in a specific patient and give stimulation precisely at critical moments to prevent seizure progression. [28]

Cannabidiol and Epilepsy

The possibility for personalised closed-loop techniques in epilepsy therapy is an especially fascinating field of study. Each person's epilepsy is unique, with different seizure kinds, triggers, and brain activity patterns. [28] Closed-loop systems have the intrinsic ability to capture and analyse individual variability, enabling for the formulation of tailored treatment plans. Closed-loop devices can adapt the timing, intensity, and stimulation site to each patient's distinct seizure patterns and needs by using patient-specific data such as EEG or ECoG recordings, genetic profiles, and clinical history. A closed-loop device, for example, can be configured to detect early indicators of seizure activity in a specific patient and give stimulation precisely at critical moments to prevent seizure progression.[29]

Clinical Trials and Evidence Supporting the Use of CBD

CBD's anticonvulsant capabilities have been thoroughly explored, resulting in the approval of a CBD-based medicine for specific epileptic conditions. Epidiolex® (cannabidiol) oral solution, a pharmaceutical-grade CBD formulation, has been approved by regulatory agencies to treat certain epileptic disorders. One of the most persuasive lines of evidence supporting the use of CBD is its ability to reduce seizures in individuals with Dravet syndrome and Lennox-Gastaut syndrome (LGS), two severe paediatric epilepsy syndromes that are notoriously difficult to manage with traditional medications. Clinical trials of Epidiolex® in Dravet syndrome and LGS revealed a significant reduction in seizure frequency compared to placebo, leading to the medication's approval for these specific indications. [30]

Recent research has also shed light on the potential use of CBD for different types of epilepsy and disorders. Observational studies and patient registries have shown that CBD reduces seizure frequency and improves seizure control in a variety of paediatric and adult epileptic populations. However, it is important to note that individual responses to CBD might vary, and not all individuals benefit equally. [31]

Concerns and Considerations Regarding the Use of CBD

While CBD appears to be a promising supplementary therapy for epilepsy, there are various issues and considerations that should be addressed. CBD may interact with certain medications metabolised by the liver's cytochrome P450 enzyme system, potentially altering their efficacy or safety. Patients and healthcare professionals must be aware of potential drug interactions while using CBD in conjunction with other medications. Although CBD is generally well accepted, some people may develop adverse effects such as lethargy, diarrhoea, and changes in appetite or weight. Most side effects are minor and temporary, although patients should be regularly watched during CBD treatment. [32]

The mechanism of action is thought to involve interactions with the endocannabinoid and other receptor systems in the brain. CBD has been shown in clinical trials and other studies to be effective in reducing seizure frequency and increasing seizure control in certain epileptic populations. However, concerns and considerations, such as potential drug interactions with CBD, side effects, and individual response variances, underscore the need for cautious patient selection, monitoring, and additional study before using it. [33]

Emerging Therapeutic Avenues

Clinical investigations have shown considerable reductions in seizure frequency and notable improvements in seizure control. Cenobamate offers a novel method to treating drug-resistant epilepsy by targeting voltage-gated sodium channels. While further research is needed to properly understand its long-term safety and efficacy, cenobamate shows promise as a useful addition to the arsenal of ASMs for epilepsy. The changing landscape of epilepsy therapy emphasises the continual efforts to give patients with a wide selection of effective therapeutic options, each suited to unique requirements and problems. As novel medications like cenobamate continue to show promise, research and innovation remain critical in improving the quality of life for people with epilepsy. [34]

Ketogenic Diet and Epilepsy

Numerous clinical investigations and trials have looked into the diet's effect on seizure control in both paediatric and adult populations with different types of drug-resistant epilepsy. A meta-analysis of various studies found that nearly half of patients on the ketogenic diet reported a considerable reduction in seizure frequency, with 10-15% reaching total seizure freedom. While the diet's reaction varies by individual, research consistently shows that the ketogenic diet can reduce seizures in a significant proportion of patients. Furthermore, current research has expanded the ketogenic diet's applicability beyond refractory epilepsy, looking at its potential benefits in other neurological illnesses such as neurodevelopmental disorders and brain tumor-related epilepsy. [35]

Potential Mechanisms of Action and Variations of the Ketogenic Diet

The precise processes by which the ketogenic diet exerts its anticonvulsant effects are unclear, however various possibilities have been offered. One of the primary elements contributing to the diet's success is the increase in ketone bodies in the

bloodstream, which are thought to have anticonvulsant qualities. Ketone bodies support neuronal function and act as an alternate fuel source for the brain. [36]

Stabilising excitability may reduce the likelihood of seizures. Furthermore, the ketogenic diet may alter the equilibrium of neurotransmitters in the brain. The diet can help reduce seizure activity and improve seizure control by increasing inhibitory neurotransmitters and decreasing excitatory neurotransmitters. [37]
As a result, the ketogenic diet remains an effective and well-established treatment option for epilepsy, particularly for drug-resistant epilepsy. Its historical function in epilepsy treatment is supported by current research, which shows that it is effective in reducing seizure frequency and increasing seizure control. While the specific mechanisms of action are still being investigated, the diet's capacity to promote ketosis and modify brain metabolism is likely a key factor in its anticonvulsant properties. The ketogenic diet demonstrates the enormous influence that dietary interventions can have in the treatment of epilepsy. For people looking for alternative or complementary treatments for their disease, the ketogenic diet may provide fresh options and hope for better seizure management and a higher quality of life. [38]

Gene Therapies for Epilepsy
Gene therapy is an innovative approach to illness treatment that involves changing or manipulating cells' genetic material. The underlying premise of gene therapy is to correct or replace defective genes that contribute to the onset or progression of a specific ailment. In epilepsy, gene therapy has the ability to address the underlying genetic defects that cause seizure disorders. Gene therapy aims to restore normal cellular function and suppress seizure formation by targeting specific epilepsy genes, paving the way for the creation of novel and more focused epilepsy treatments. [39]
CRISPR-Cas9 allows researchers to edit or remove epilepsy-related genes and study their impact on seizure susceptibility. For epilepsy, gene editing techniques are being used to investigate the involvement of specific genes involved in the illness. Researchers can explore how changes in genes related with ion channels, neurotransmitter receptors, or cellular signalling pathways contribute to epilepsy. Gene editing technologies are being utilised to fix disease-causing mutations in patient-derived cells or animal models. This could lead to personalised gene therapy for specific genetic abnormalities. [40]

Safety and Efficacy of Gene Therapies

While gene therapy for epilepsy is still in its early stages of development, preliminary experiments in animal models have yielded promising results. Animal models with specific epilepsy-related genetic alterations have been treated with gene therapy approaches, resulting in reduced seizure frequency and enhanced seizure control. valuable insights into the possible therapeutic benefits of gene treatments and highlighted potential target genes for further research. Several gene therapy trials for epilepsy are now underway or planned. The purpose of these trials is to assess the safety and efficacy of gene treatments in humans with certain hereditary types of epilepsy. One significant example is the creation of AAV vectors as a delivery mechanism for gene treatments. [41]

Optogenetics in Epilepsy Research
Optogenetics is a cutting-edge approach that uses genetics and optics to control the activity of individual neurons in living tissue through light. This groundbreaking strategy includes genetically modifying neurons to create light-sensitive proteins known as opsins, which respond to certain light wavelengths. When activated by light, these opsins can stimulate or inhibit the activity of the targeted neurons. Optogenetics enables precise and real-time manipulation of neural circuits, giving researchers unparalleled control over studying the function of specific brain regions and the mechanisms underlying numerous neurological illnesses, including epilepsy. [42]
Terneurons influence network excitability and seizure susceptibility. Researchers have demonstrated that using optogenetic methods to target these interneurons can either augment or decrease seizure activity, providing insights into future therapeutic strategies. Optogenetics has been useful in studying the dynamics of brain circuits during seizures. Researchers obtained a better grasp of how seizures spread via interconnected brain regions and how specific circuit defects contribute to epileptic episodes by recording and manipulating neuronal activity simultaneously with optogenetics. [43]

Future Possibilities of Optogenetics in Clinical Applications
Opogenetics' clinical uses in epilepsy are both promising and problematic. While optogenetics has mostly been employed in preclinical research, its application in clinical practice confronts major challenges.[44] Directly applying optogenetics to human brains is currently not practical due to the necessity for gene delivery and light-delivery systems, which would necessitate intrusive procedures. However, the findings from optogenetics investigations in animal models can help to build more targeted and effective medicines. Optogenetics research can assist uncover specific brain targets or circuit components that can be controlled by alternate ways, such as targeted pharmaceutical therapies or neuromodulation techniques.[45]
This hybrid strategy has the potential to provide personalised and adaptive therapy for those with drug-resistant epilepsy.[5] In the future, developments in non-invasive approaches for optogenetic activation, as well as the creation of novel light-sensitive proteins, may allow for the non-invasive application of optogenetics to human brains. Although this goal remains in the realm of fundamental research, it holds promise for the future of epilepsy treatment and other neurological illnesses. Optogenetics is a useful tool in epilepsy research, allowing for precise regulation of brain activity to investigate the mechanisms behind seizures. By merging optogenetics with other neurostimulation methods, such as responsive neurostimulation, the future potential for personalised and adaptable epilepsy treatments seem exciting. [46]

DISCUSSIONS

In this comprehensive analysis, we looked at a variety of novel therapies for epilepsy management. We presented an overview of existing epileptic treatment techniques, emphasising the limitations of ASMs and the need for new strategies to address drug-resistant epilepsy. Importantly, poor medication compliance in ASMs might impair treatment efficacy over time and contribute to treatment resistance. It is commonly acknowledged that continuous and timely adherence to prescribed drug regimens is critical for attaining the best outcomes in epilepsy therapy. When patients do not adhere to their medication schedule as advised, the therapeutic levels of antiseizure drugs in their system may become insufficient, resulting in breakthrough seizures and poor seizure control.

Over time, this can lead to a diminished response to medication, making the illness more resistant to therapy and prompting changes to the treatment strategy. We then focused on three new therapies: RNS, VNS, and DBS, reviewing their mechanisms of action, clinical evidence, and prospective benefits for various epileptic disorders. Next, we looked at CBD's involvement in epilepsy treatment, focusing on its pharmacology, clinical trials supporting its usage in certain epileptic syndromes, and considerations for supplementary therapy. We investigated the possibility of gene treatments and optogenetics in epilepsy research.

Gene therapies are a promising way to target specific genes related with epilepsy, with recent advances in gene editing techniques indicating the potential for precise and personalised treatments. Optogenetics, on the other hand, has enabled ground-breaking research into seizure mechanisms by allowing for real-time modulation of brain circuits in animal models. Although direct therapeutic uses of optogenetics in humans are currently difficult, the information collected from this study may aid in the development of future medicines.

Furthermore, current research into CBD and other cannabinoids may reveal new therapeutic applications and optimise dose regimes for various epileptic conditions. Continued clinical trials will provide vital data supporting CBD's long-term safety and efficacy, as well as its potential use as a monotherapy or complementary treatment. Finally, collaboration among researchers, doctors, and industry partners is critical for improving epilepsy care.

CONCLUSIONS

Epilepsy care has advanced significantly in recent years because to novel medications. Researchers have broadened the frontiers of epilepsy treatment by investigating responsive neurostimulation and neuromodulation techniques such as VNS and DBS, as well as the use of CBD as an anticonvulsant drug and the cutting-edge fields of gene treatments and optogenetics. The importance of remaining current on developing trends cannot be emphasised, as new findings may provide hope for individuals with drug-resistant epilepsy and open the door to more tailored and effective therapy. Future research should focus on improving existing treatments, investigating combination techniques, and leveraging AI and machine intelligence to improve epilepsy care. Collaborative efforts among researchers, physicians, and industry partners will be critical for realising the full promise of these breakthrough medicines and pushing epilepsy care to new heights. Finally, the purpose of continued research and improvement in epilepsy care is to enhance the lives of people with epilepsy by giving them more seizure control, a higher quality of life, and renewed hope for a better future.

References

1. Devinsky, O.; Vezzani, A.; O'Brien, T.J.; Jette, N.; Scheffer, I.E.; de Curtis, M.; Perucca, P. Epilepsy. Nat. Rev. Dis. Prim. **2018**, 4, 18024.Ghosh, S.; Sinha, J.K.; Khan, T.; Devaraju, K.S.; Singh, P.; Vaibhav, K.; Gaur, P. Pharmacological and Therapeutic Approaches inthe Treatment of Epilepsy. Biomedicines **2021**, 9, 470. [CrossRef] [PubMed]

2. Reddy, D.S. Therapeutic and Clinical Foundations of Cannabidiol Therapy for Difficult-to-Treat Seizures in Children and Adultswith Refractory Epilepsies. Exp. Neurol. **2023**, 359, 114237. [CrossRef] [PubMed]

3. Fattorusso, A.; Matricardi, S.; Mencaroni, E.; Dell'Isola, G.B.; Di Cara, G.; Striano, P.; Verrotti, A. The Pharmacoresistant Epilepsy: An Overview on Existant and New Emerging Therapies. Front. Neurol. **2021**, 12, 674483. [CrossRef]

4. Gidal, B.; Klein, P.; Hirsch, L.J. Seizure Clusters, Rescue Treatments, Seizure Action Plans: Unmet Needs and Emerging Formulations. Epilepsy Behav. **2020**, 112, 107391. [CrossRef]

5. Anwar, H.; Khan, Q.U.; Nadeem, N.; Pervaiz, I.; Ali, M.; Cheema, F.F. Epileptic Seizures. Discoveries **2020**, 8, e110. [CrossRef]

6. Mishra, P.; Sinha, J.K.; Rajput, S.K. Efficacy of Cicuta Virosa Medicinal Preparations against Pentylenetetrazole-Induced Seizures.
Epilepsy Behav. **2021**, 115, 107653. [CrossRef]

7. Baftiu, A.; Lima, M.H.; Svendsen, K.; Larsson, P.G.; Johannessen, S.I.; Landmark, C.J. Safety Aspects of Antiepileptic Drugs-a Population-Based Study of Adverse Effects Relative to Changes in Utilisation. Eur. J. Clin. Pharmacol. **2019**, 75, 1153–1160. [CrossRef] [PubMed]

8. Stevelink, R.; Koeleman, B.P.C.; Sander, J.W.; Jansen, F.E.; Braun, K.P.J. Refractory Juvenile Myoclonic Epilepsy: A Meta-Analysisof Prevalence and Risk Factors. Eur. J. Neurol. **2019**, 26, 856–864. [CrossRef]

9. Okiah, L.; Olowo, S.; Iramiot, S.J.; Nekaka, R.; Ssenyonga, L.V.N. Lived Experiences of Caregivers of Persons with Epilepsy At-tending an Epilepsy Clinic at a Tertiary Hospital, Eastern Uganda: A Phenomenological Approach. PLoS ONE **2023**, 18, e0274373. [CrossRef]

10. Löscher, W.; Potschka, H.; Sisodiya, S.M.; Vezzani, A. Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, andNew Innovative Treatment Options. Pharmacol. Rev. **2020**, 72, 606–638. [CrossRef] [PubMed]

11. Urzì Brancati, V.; Pinto Vraca, T.; Minutoli, L.; Pallio, G. Polymorphisms Affecting the Response to Novel

Antiepileptic Drugs. Int.
J. Mol. Sci. **2023**, 24, 2535. [CrossRef] [PubMed]

12. Chen, T.-S.; Lai, M.-C.; Huang, H.-Y.I.; Wu, S.-N.; Huang, C.-W. Immunity, Ion Channels and Epilepsy. Int. J. Mol. Sci. **2022**,
23, 6446. [CrossRef]

13. Kobayashi, K.; Endoh, F.; Ohmori, I.; Akiyama, T. Action of Antiepileptic Drugs on Neurons. Brain Dev. **2020**, 42, 2–5. [CrossRef]
14. Shih, P.; Francis-Auton, E.; Nikpour, A.; Herkes, G.; Bleasel, A.; Rapport, F. Enhancing Quality of Life among Epilepsy Surgery Patients: Interlinking Multiple Social and Relational Determinants. Epilepsy Behav. **2024**, 102, 106721. [CrossRef]
15. Sinha, N.; Johnson, G.W.; Davis, K.A.; Englot, D.J. Integrating Network Neuroscience Into Epilepsy Care: Progress, Barriers, and Next Steps. Epilepsy Curr. **2022**, 22, 272–278. [CrossRef] [PubMed]
16. for Treatment of Pediatric Drug-Resistant Epilepsy. Epilepsy Behav. Case Rep. **2018**, 10, 21–24. [CrossRef]
17. Li, Y.; Zhang, S.; Snyder, M.P.; Meador, K.J. Precision Medicine in Women with Epilepsy: The Challenge, Systematic Review, and Future Direction. Epilepsy Behav. **2021**, 118, 107928. [CrossRef]
18. Manzari, M.T.; Shamay, Y.; Kiguchi, H.; Rosen, N.; Scaltriti, M.; Heller, D.A. Targeted Drug Delivery Strategies for Precision Medicines. Nat. Rev. Mater. **2024**, 6, 351–370. [CrossRef]
19. Perucca, E.; Perucca, P.; White, H.S.; Wirrell, E.C. Drug Resistance in Epilepsy. Lancet Neurol. **2023**, 22, 723–734. [CrossRef]
20. Madireddy, S.; Madireddy, S. Therapeutic Strategies to Ameliorate Neuronal Damage in Epilepsy by Regulating Oxidative Stress, Mitochondrial Dysfunction, and Neuroinflammation. Brain Sci. **2023**, 13, 784. [CrossRef] [PubMed]
21. Menon, S.; Sander, J.W. Effects of the COVID-19 Pandemic on Medication Adherence: In the Case of Antiseizure Medications, A Scoping Review. Seizure **2021**, 93, 81–87. [CrossRef] [PubMed]
22. Kusyk, D.M.; Meinert, J.; Stabingas, K.C.; Yin, Y.; Whiting, A.C. Systematic Review and Meta-Analysis of Responsive Neurostimu-lation in Epilepsy. World Neurosurg. **2022**, 167, e70–e78. [CrossRef]
23. Vessell, M.; Willett, A.; Chapman, B.; Bina, R.; Ball, T.; Mutchnick, I.; Neimat, J.S. Evidence for Thalamic Responsive Neurostimu-lation in Treatment of Adult and Pediatric Epilepsy. Ster. Funct. Neurosurg. **2023**, 101, 75–85. [CrossRef] [PubMed]
24. Xue, T.; Chen, S.; Bai, Y.; Han, C.; Yang, A.; Zhang, J. Neuromodulation in Drug-Resistant Epilepsy: A Review of Current Knowledge. Acta Neurol. Scand. **2022**, 146, 786–797. [CrossRef]
25. Razavi, B.; Rao, V.R.; Lin, C.; Bujarski, K.A.; Patra, S.E.; Burdette, D.E.; Geller, E.B.; Brown, M.-G.M.; Johnson, E.A.; Drees, C.; et al. Real-World Experience with Direct Brain-Responsive Neurostimulation for Focal Onset Seizures. Epilepsia **2020**, 61, 1749–1757. [CrossRef]
26. Rincon, N.; Barr, D.; Velez-Ruiz, N. Neuromodulation in Drug Resistant Epilepsy. Aging Dis. **2021**, 12, 1070–1080. [CrossRef]
27. Csernyus, B.; Szabó, Á.; Fiáth, R.; Zátonyi, A.; Lázár, C.; Pongrácz, A.; Fekete, Z. A Multimodal, Implantable Sensor Array and Measurement System to Investigate the Suppression of Focal Epileptic Seizure Using Hypothermia. J. Neural. Eng. **2021**, 18, 0460c3. [CrossRef]
28. Wu, H.; Adler, S.; Azagury, D.E.; Bohon, C.; Safer, D.L.; Barbosa, D.A.N.; Bhati, M.T.; Williams, N.R.; Dunn, L.B.; Tass, P.A.; et al. Brain-Responsive Neurostimulation for Loss of Control Eating: Early Feasibility Study. Neurosurgery **2020**, 87, 1277–1288. [CrossRef]
29. Alcala-Zermeno, J.L.; Starnes, K.; Gregg, N.M.; Worrell, G.; Lundstrom, B.N. Responsive Neurostimulation with Low-Frequency Stimulation. Epilepsia **2023**, 64, e16–e22. [CrossRef] [PubMed]
30. Jarosiewicz, B.; Morrell, M. The RNS System: Brain-Responsive Neurostimulation for the Treatment of Epilepsy. Expert Rev. Med. Devices **2021**, 18, 129–138. [CrossRef] [PubMed]
31. Ngadimon, I.W.; Aledo-Serrano, A.; Arulsamy, A.; Mohan, D.; Khoo, C.S.; Cheong, W.L.; Shaikh, M.F. An Interplay Between Post-Traumatic Epilepsy and Associated Cognitive Decline: A Systematic Review. Front. Neurol. **2024**, 13, 827571. [CrossRef] [PubMed]
32. Kerezoudis, P.; Gyftopoulos, A.; Alexander, A.Y.; Keith Starnes, D.; Nickels, K.C.; Worrell, G.A.; Wirrell, E.C.; Lundstrom, B.N.; Van Gompel, J.J.; Miller, K.J. Safety and Efficacy of Responsive Neurostimulation in the Pediatric Population: Evidence from Institutional Review and Patient-Level Meta-Analysis. Epilepsy Behav. **2022**, 129, 108646. [CrossRef]
33. Panov, F.; Ganaha, S.; Haskell, J.; Fields, M.; La Vega-Talbott, M.; Wolf, S.; McGoldrick, P.; Marcuse, L.; Ghatan, S. Safety of Responsive Neurostimulation in Pediatric Patients with Medically Refractory Epilepsy. J. Neurosurg. Pediatr. **2020**, 26, 525–532. [CrossRef]
34. Piper, R.J.; Richardson, R.M.; Worrell, G.; Carmichael, D.W.; Baldeweg, T.; Litt, B.; Denison, T.; Tisdall, M.M. Towards Network-Guided Neuromodulation for Epilepsy. Brain **2022**, 145, 3347–3362. [CrossRef]
35. Kwon, C.-S.; Schupper, A.J.; Fields, M.C.; Marcuse, L.V.; La Vega-Talbott, M.; Panov, F.; Ghatan, S. Centromedian Thalamic Responsive Neurostimulation for Lennox-Gastaut Epilepsy and Autism. Ann. Clin. Transl.

Neurol. **2020**, 7, 2035–2040. [CrossRef]

36.Parihar, J.; Agrawal, M.; Samala, R.; Chandra, P.S.; Tripathi, M. Role of Neuromodulation for Treatment of Drug-Resistant Epilepsy. Neurol. India **2024**, 68, S249–S258. [CrossRef] [PubMed

37.Bonaz, B.; Sinniger, V.; Pellissier, S. Therapeutic Potential of Vagus Nerve Stimulation for Inflammatory Bowel Diseases. Front.Neurosci. **2021**, 15, 650971. [CrossRef]

38.Butt, M.F.; Albusoda, A.; Farmer, A.D.; Aziz, Q. The Anatomical Basis for Transcutaneous Auricular Vagus Nerve Stimulation.
J. Anat. **2020**, 236, 588–611. [CrossRef]

39.Lee, J.; Raycraft, L.; Johnson, A.W. The Dynamic Regulation of Appetitive Behavior through Lateral Hypothalamic Orexin and Melanin Concentrating Hormone Expressing Cells. Physiol. Behav. **2021**, 229, 113234. [CrossRef]

40.Yang, H.; Shi, W.; Fan, J.; Wang, X.; Song, Y.; Lian, Y.; Shan, W.; Wang, Q. Transcutaneous Auricular Vagus Nerve Stimulation (Ta-VNS) for Treatment of Drug-Resistant Epilepsy: A Randomized, Double-Blind Clinical Trial. Neurotherapeutics **2023**, 20, 870–880. [CrossRef] [PubMed]

41.Fan, J.-J.; Shan, W.; Wu, J.-P.; Wang, Q. Research Progress of Vagus Nerve Stimulation in the Treatment of Epilepsy. CNS Neurosci. Ther. **2019**, 25, 1222–1228. [CrossRef] [PubMed]

42.Fahoum, F.; Boffini, M.; Kann, L.; Faini, S.; Gordon, C.; Tzadok, M.; El Tahry, R. VNS Parameters for Clinical Response in Epilepsy. Brain Stimul. **2022**, 15, 814–821. [CrossRef]

43.Fisher, B.; DesMarteau, J.A.; Koontz, E.H.; Wilks, S.J.; Melamed, S.E. Responsive Vagus Nerve Stimulation for Drug Resistant Epilepsy: A Review of New Features and Practical Guidance for Advanced Practice Providers. Front. Neurol. **2020**, 11, 610379.[CrossRef]

44.Canal-Alonso, Á.; Casado-Vara, R.; Castellano, O.; Herrera-Santos, J.; Gonçalves, J.; Màrquez-Sànchez, S.; Gonçalves, J.M.; Corchado, J.M. An Affordable Implantable Vagus Nerve Stimulator System for Use in Animal Research. Philos. Trans. A Math. Phys. Eng. Sci. **2022**, 380, 20210010. [CrossRef]

45.Afra, P.; Adamolekun, B.; Aydemir, S.; Watson, G.D.R. Evolution of the Vagus Nerve Stimulation (VNS) Therapy System Technology for Drug-Resistant Epilepsy. Front. Med. Technol. **2021**, 3, 696543. [CrossRef] [PubMed]

46.Ji, T.; Yang, Z.; Liu, Q.; Liao, J.; Yin, F.; Chen, Y.; Zou, L.; Li, B.; Gao, Y.; Shu, X.; et al. Vagus Nerve Stimulation for Pediatric Patients with Intractable Epilepsy between 3 and 6 Years of Age: Study Protocol for a Double-Blind, Randomized Control Trial. Trials **2019**, 20, 44. [CrossRef] [PubMed]